Roche pays Zymeworks $55M upfront in deal worth up to $813M

· Health · Switzerland · United States

Swiss pharma Roche is teaming up with Zymeworks, paying $55 million upfront for worldwide rights to a preclinical trispecific T cell engager that could compete head-to-head with Amgen's Imdelltra, Endpoints News reported. The deal could be worth up to $813 million including milestones. The arrangement is described as another in a string of Roche deals, showing the company's appetite for early-stage oncology assets. T cell engagers are bispecific or multispecific antibodies that redirect immune cells to kill tumor cells; trispecific versions add a third binding target. The asset is still preclinical, so the transaction buys optionality rather than near-term revenue. The comparison with Imdelltra underscores how crowded the T cell engager field has become.

Why it matters：Roche is paying for optionality in the T cell engager race, a field where a preclinical asset can still be valued against an approved competitor, showing how fierce the competition for next-generation oncology platforms has become.

Key points

  • Roche pays $55 million upfront for worldwide rights.
  • Total deal value can reach $813 million with milestones.
  • The asset is a preclinical trispecific T cell engager that could rival Amgen's Imdelltra.

Sources (original reporting)

More stories from this day